Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study

References

• Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29–30):513–520.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. doi:10.1016/S0140-6736(18)31550-2
   PubMed Web of Science ®Google Scholar
• García-Layana A, Cabrera-López F, García-Arumí J, Arias-Barquet L, Ruiz-Moreno JM. Early and intermediate age-related macular degeneration: update and clinical review. Clin Interv Aging. 2017;12:1579–1587. doi:10.2147/CIA.S142685
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921–927. doi:10.1016/j.ophtha.2009.10.007
   PubMed Web of Science ®Google Scholar
• Likhar N, Mothe RK, Kanukula R, et al. The prevalence of age-related macular degeneration in Indian population: a systematic review. Value Health. 2015;18(3):A180. doi:10.1016/j.jval.2015.03.1041
   PubMed Web of Science ®Google Scholar
• Gupta SK, Murthy GV, Morrison N, et al. Prevalence of early and late age-related macular degeneration in a rural population in northern India: the INDEYE feasibility study. Invest Ophthalmol Vis Sci. 2007;48(3):1007–1011. doi:10.1167/iovs.06-0712
   PubMed Web of Science ®Google Scholar
• Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313–1330. doi:10.2147/CIA.S143508
   PubMed Web of Science ®Google Scholar
• Hernández-Zimbrón LF, Zamora-Alvarado R, Ochoa-de la paz L, et al. Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longev. 2018;2018:8374647. doi:10.1155/2018/8374647
   PubMed Web of Science ®Google Scholar
• Phan LT, Broadhead GK, Hong TH, Chang AA. Predictors of visual acuity after treatment of neovascular age-related macular degeneration - current perspectives. Clin Ophthalmol. 2021;15:3351–3367. doi:10.2147/OPTH.S205147
   PubMed Web of Science ®Google Scholar
• Gil-Martínez M, Santos-Ramos P, Fernández-Rodríguez M, et al. Pharmacological advances in the treatment of age-related macular degeneration. Curr Med Chem. 2020;27(4):583–598. doi:10.2174/0929867326666190726121711
   PubMed Web of Science ®Google Scholar
• Parravano M, Costanzo E, Scondotto G, Trifirò G, Virgili G. Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update. BioDrugs. 2021;35(6):673–692. doi:10.1007/s40259-021-00499-2
   PubMed Web of Science ®Google Scholar
• Yeung L, Hsieh YT, Yang CH, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120(12):2061–2071. doi:10.1016/j.jfma.2021.06.012
   PubMed Web of Science ®Google Scholar
• Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(21):8242. doi:10.3390/ijms21218242
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration - Indian real-world experience: the BRAILLE Study. Clin Ophthalmol. 2021;15:3787–3795. doi:10.2147/OPTH.S328160
   PubMed Web of Science ®Google Scholar
• Monés J, Singh RP, Bandello F, et al. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243(1):1–8. doi:10.1159/000502747
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963–976. doi:10.1016/j.ophtha.2019.12.031
   PubMed Web of Science ®Google Scholar
• Recommendations of the 39th SEC (Ophthalmology) Meeting, 22.06.2020 at CDSCO HQ New Delhi. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/39thSECOphthalmologyRecommendation%2022.06.2020.pdf. Accessed April 17, 2022.
   Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52(12):3402–3408.
   PubMed Web of Science ®Google Scholar
• Borras L, Gunde T, Tietz J, et al. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem. 2010;285(12):9054–9066. doi:10.1074/jbc.M109.072876
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicentre, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
   PubMed Web of Science ®Google Scholar
• Baumal CR, Sørensen TL, Karcher H, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol. 2022;00:1–17.
   Google Scholar
• Zubricky R, McCoy J, Donkor R, et al. Real-world frequency and management of ocular adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab [published online ahead of print, 2023 Jun 13]. Ophthalmol Ther. 2023. doi:10.1007/s40123-023-00741-w
   PubMed Web of Science ®Google Scholar
• Finger RP, Dennis N, Freitas R, et al. Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(8):3425–3448. doi:10.1007/s12325-022-02193-3
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar N, Parachuri N, et al. Brolucizumab-early real-world experience: BREW study. Eye. 2021;35(4):1045–1047. doi:10.1038/s41433-020-1111-x
   PubMed Web of Science ®Google Scholar
• Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2022;106(9):1288–1294. doi:10.1136/bjophthalmol-2020-318672
   PubMed Web of Science ®Google Scholar
• Enríquez AB, Baumal CR, Crane AM, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(4):441–448. doi:10.1001/jamaophthalmol.2020.7085
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1):6759. doi:10.1038/s41598-021-86014-7
   PubMed Web of Science ®Google Scholar
• Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice. Front Pharmacol. 2021;12:720345. doi:10.3389/fphar.2021.720345
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43–58.e1. doi:10.1016/j.ajo.2009.01.024
   PubMed Web of Science ®Google Scholar
• Anantharaman G, Sheth J, Bhende M, et al. Polypoidal choroidal vasculopathy: pearls in diagnosis and management. Indian J Ophthalmol. 2018;66(7):896–908. doi:10.4103/ijo.IJO_1136_17
   PubMed Web of Science ®Google Scholar
• Bilgic A, Kodjikian L, Srivastava S, et al. Initial pro re nata brolucizumab for exudative AMD: the PROBE Study. J Clin Med. 2021;10(18):4153. doi:10.3390/jcm10184153
   PubMed Web of Science ®Google Scholar
• Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA Study. J Clin Med. 2021;10(13):2758. doi:10.3390/jcm10132758
   PubMed Web of Science ®Google Scholar
• Walter S, Saba N Efficacy and durability of brolucizumab in patients being transitioned from prior anti-VEGF therapy; 2021.
   Google Scholar
• Rübsam A, Rau S, Pilger D, et al. Early OCT angiography changes of macular neovascularization in patients with exudative AMD Treated with brolucizumab in a real-world setting. JOphthalmol. 2022;2022:1–9. doi:10.1155/2022/2659714
   Web of Science ®Google Scholar
• Abdin AA, Aljundi W, Jawhari KE, Suffo S, Weinstein I, Seitz B. First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol. 2012;13:860784.
   Google Scholar
• Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration - Indian real-world experience: the BRAILLE Study - fifty-two-week outcomes. Clin Ophthalmol. 2022;16:4303–4313. doi:10.2147/OPTH.S395577
   PubMed Web of Science ®Google Scholar
• Pagenax [pack insert]. Mumbai, India: Novartis Healthcare Pvt. Ltd.; 2022.
   Google Scholar
• National health estimates (2018–2019) released. Press Information Bureau (pib.gov.in). Ministry of health and family welfare; 2022. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1858770. Accessed July 5, 2023.
   Google Scholar